Increased regulatory activity of the calcineurin/NFAT pathway in human heart failure

Holger Diedrichs1, Mei Chi, Birgit Boelck

  • 1Laboratory of Muscle Research and Molecular Cardiology, University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany.

Abstract

Insights

The calcineurin signaling pathway is activated in human heart failure (dilated cardiomyopathy). This involves increased calcineurin activity, GATA-4 expression, and NFAT-3 nuclear translocation, indicating pathway activation in cardiac dysfunction.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cell Signaling

Background:

  • Cardiac hypertrophy can lead to impaired cardiac function.
  • Molecular pathways of cardiac hypertrophy are not fully understood.
  • The calcineurin/NFAT pathway is implicated in cardiac hypertrophy in animal models.

Purpose of the Study:

  • To investigate the activation of the calcineurin pathway in human heart failure.
  • To compare calcineurin pathway markers in dilated cardiomyopathy (DCM) versus non-failing hearts.

Main Methods:

  • Analyzed human left ventricular myocardium from DCM patients and non-failing controls.
  • Measured calcineurin enzymatic activity.
  • Determined protein expression of calcineurin B, NFAT-3, and GATA-4.

Main Results:

  • Calcineurin activity was 80% higher in DCM hearts.
  • Increased protein expression of calcineurin B and GATA-4 in DCM.
  • NFAT-3 showed increased levels in nuclear extracts of DCM hearts, indicating nuclear translocation.

Conclusions:

  • The calcineurin signaling pathway is activated in human heart failure (DCM).
  • Activation involves increased calcineurin activity and GATA-4 expression.
  • Subcellular redistribution of NFAT-3 to the nucleus signifies regulatory activation in DCM.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...